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C a s e  R e p o R t
A 56-year-old male presented to the emergency room (ER) complaining of left 
upper quadrant abdominal pain. Among other examinations, a cardiology consulta-
tion was requested because of a significant ST-segment elevation in the precordial 
lead V2.
The ECG was repeated showing a morphology of type-2 (saddleback) Brugada 
syndrome (Fig. 1). A modified ECG recording, obtained by placing the right precordial 
leads in higher positions at the second and third intercostal spaces, revealed a type-1 
(coved) Brugada syndrome morphology (Fig. 2).
While the patient still in the ER, he started feeling anxious and within seconds 
he sustained a syncopal episode in sitting position, lasting about 30 sec with prompt 
and full recovery. At this time he was not connected to an external monitor and the 
underlying rhythm could not be witnessed. The ER physician reported that the patient 
had no pulse during the episode and that he was frightened when he woke up but not 
disoriented.
The patient was then transferred to the cardiac care unit (CCU) where he was 
placed on rhythm monitoring for 24 hours without further events. Cardiac enzymes 
remained normal, including three consecutive cTnI measurements, over the first 24 
hours. Blood counts and biochemistry revealed no pathological values.
The next day the patient had an echocardiogram that was interpreted as normal 
for his age, noting that the right ventricle was of normal dimensions and contraction 
without any wall motion abnormality suspect of right ventricular cardiomyopathy. 
Subsequently he was submitted to a treadmill stress test. Using the Bruce protocol, 
he achieved a heart rate of 87% of his predicted for his age target rate and performed 
a satisfactory workload of 11 METS for 9.5 min. The Brugada type 1 morphology on 
the ECG remained unchanged during the whole process including the recovery period 
after the exercise test.
After completing the stress test and leaving the exercise room, while standing 
in the waiting room, before being transferred back to the cardiac ward, the patient 
suddenly developed another syncopal episode. He was immediately connected to a 
cardiac monitor which revealed sinus bradycardia of about 30/min. His recovery was 
again rapid and full. As vasovagal syncope was suspected as the cause of these epi-
sodes, the next day the patient underwent a tilt-table test. During tilting the patient 
remained asymptomatic for the first 30 min in the standing position. It took 8 min 
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FIGURe 2. A modified ECG recording was obtained by placing the right precordial leads at the second and third intercostal spaces, 
revealing a type-1 (coved) Brugada pattern
FIGURe 1. ECG showing a morphology of type-2 (saddleback) Brugada pattern in lead V2.
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into the isoproterenol infusion period and while titrating the 
dose up to 3 mcg/min, when his heart rate increased from 
87/min to 115/min. At this time he started having prodromal 
symptoms like sweating, getting pale and his blood pressure 
fell rapidly, while he became relatively bradycardic. The test 
was terminated by putting the patient in a supine position, to 
prevent another syncopal spell. Thus, a diagnosis of vasovagal 
syncope of mixed (cardioinhibitory & vasodepressive) type 
was reached. Due to the history of syncopal episodes, and the 
Brugada type I ECG pattern, the patient was referred for an 
electrophysiology study. Polymorphic ventricular tachycardia 
was induced and the patient subsequently had an automatic 
defibrillator (ICD) implanted for prophylaxis from sudden 
cardiac death.
D I s C U s s I o N
The Brugada syndrome is characterized by ST-segment 
elevation in the right precordial leads V1 through V3 and an 
episode of venricular tachyarrythmia in the absence of struc-
tural heart disease.1-3 Patients with spontaneously or inducible 
Brugada type-1 morphology are at high risk of polymorphic 
ventricular tachycardia (and less frequently for monomorphic 
ventricular or supraventricular tachycardias), which when it is 
self-terminating can present as syncope. According to the 2009 
guidelines of the European Society of Cardiology (ESC) on 
syncope, neurally-mediated syncope (NMS) is the most com-
mon cause of all syncopal episodes,4 having a quite favorable 
prognosis. Individuals who fulfill the ECG criteria of the 
Brugada syndrome and have episodes of syncope of cardiac 
origin should proceed to ICD implantation without the need 
of an EPS study.3 However, it behooves us to determine the 
precise cause of syncope even in patients with the Brugada 
syndrome, as they are also entitled to have syncope of other 
more common causes, like NMS, and not necessarily suffer 
from ventricular tachyarrhythmias.
Two recent reports studying the incidence of NMS in a 
patient population with the Brugarda-type ECG pattern,5,6 
reported a similar incidence of NMS with that noted in the 
general population. This observation might suggest that 
the most common cause of syncope in Brugada patients is 
NMS. Of course, vasovagal syncope is considered benign in 
the general population in the absence of underlying cardiac 
pathology, but in patients with the Brugada syndrome things 
may be different since a vagally-induced episode of bradycar-
dia could be a potential trigger factor for lethal ventricular 
arrhythmias. This dilemma seems to exist since 20017,8 and 
todate it remains unresolved. As the Brugada brothers have 
proposed,8 it may be better to overprotect the patient with 
Brugada syndrome and vasovagal syncope by implanting an 
ICD than just accepting the vasovagal origin of all syncopal 
episodes in this particular patient population.
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